Education
About Us
Working with TipRanks
Follow Us
NeuroOne Medical Technologies (NMTC)
NASDAQ:NMTC
RESEARCH TOOLSreports
Top Page
NeuroOne Medical Technologies
(NASDAQ:NMTC)
Rating:46Neutral
Price Target:
$0.50
▼( -19.35% Downside)
NeuroOne Medical Technologies (NMTC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$31.03M
Dividend YieldN/A
Average Volume (3M)345.72K
Price to Earnings (P/E)―
Beta (1Y)1.45
Revenue Growth135.03%
EPS Growth60.67%
CountryUS
Employees17
SectorHealthcare
Sector Strength40
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.07
Shares Outstanding49,817,837
10 Day Avg. Volume315,537
30 Day Avg. Volume345,717
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)17.18
Price to Sales (P/S)0.00
P/FCF Ratio0.26
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue1.59
Enterprise Value/Gross Profit9.60
Enterprise Value/Ebitda-0.83
Forecast
1Y Price Target
$1.45Price Target Upside133.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
NeuroOne Medical Technologies Business Overview & Revenue Model
Company DescriptionNeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator for use with NeuroOne's combination recording and ablation electrode to record brain activity and ablate brain tissue using the same electrode. The company is based in Eden Prairie, Minnesota.
How the Company Makes MoneyNeuroOne Medical Technologies generates revenue primarily through the sale of its medical devices and technologies to hospitals, clinics, and healthcare providers. Key revenue streams include sales of its thin-film electrode systems, which are used in various neurological procedures. The company also potentially earns income from partnerships, collaborations, and licensing agreements with other firms in the medical technology sector. These partnerships can provide additional funding, resources, and distribution channels, contributing to NeuroOne's earnings. Furthermore, the company might receive grants or research funding aimed at advancing its technology and expanding its product offerings.
NeuroOne Medical Technologies Financial Statement Overview
Summary
NeuroOne Medical Technologies shows rapid revenue growth, but faces significant profitability challenges with negative EBIT and net income margins. The balance sheet is moderately leveraged with strong cash holdings, yet continuous net losses pose risks. Cash flow improvements are evident, but sustainability remains a concern.Income Statement
NeuroOne Medical Technologies has shown a significant increase in revenue over the Trailing-Twelve-Months (TTM), with revenue growing from $3.45 million to $1.39 billion. However, the company continues to face substantial profitability challenges, with negative EBIT and net income margins, indicating ongoing operational losses. The gross profit margin is positive, but the high level of operating expenses is impacting net profitability.30
Negative
Balance Sheet
The balance sheet of NeuroOne is moderately leveraged with a debt-to-equity ratio of 0.18, indicating a conservative use of debt. The company's equity ratio stands at 25.3%, reflecting a solid base of equity relative to total assets. However, the continuous net losses are a concern for the sustainability of equity. Cash holdings are strong, providing liquidity support.45
Neutral
Cash Flow
The company has shown improvement in operating cash flow, turning positive in the TTM, which is a positive indicator of operational efficiency. However, the free cash flow has only recently become positive, and historical negative free cash flow highlights cash flow management challenges. The operating cash flow to net income ratio suggests that cash generation is better than what income figures indicate.35
Negative
| Breakdown | |||||
| TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 5.76M | 3.45M | 1.95M | 171.17K | 178.15K | 1.93M | Gross Profit |
| 3.12M | 1.08M | 456.52K | -70.79K | -97.75K | 63.12K | EBIT |
| -6.58M | -11.89M | -11.96M | -10.03M | -10.22M | -4.90M | EBITDA |
| -5.72M | -11.84M | -11.76M | -9.91M | -9.80M | -4.85M | Net Income Common Stockholders |
| -6.60M | -12.32M | -11.86M | -10.00M | -9.95M | -13.64M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 2.43M | 1.46M | 5.32M | 11.14M | 6.90M | 4.04M | Total Assets |
| 5.39M | 5.37M | 8.10M | 12.82M | 7.94M | 4.76M | Total Debt |
| 121.90K | 260.16K | 184.40K | 202.90K | 315.67K | 1.32M | Net Debt |
| -2.31M | -1.20M | -5.14M | -7.96M | -6.59M | -2.72M | Total Liabilities |
| 1.54M | 4.55M | 1.85M | 3.22M | 1.38M | 2.69M | Stockholders Equity |
| 3.85M | 822.01K | 6.25M | 9.60M | 6.55M | 2.07M |
| Cash Flow | Free Cash Flow | ||||
| -4.95M | -11.13M | -13.27M | -7.79M | -8.67M | -3.55M | Operating Cash Flow |
| -4.88M | -11.01M | -12.89M | -7.52M | -8.60M | -3.43M | Investing Cash Flow |
| -79.29K | -120.20K | 2.65M | -3.24M | -67.08K | -122.43K | Financing Cash Flow |
| 4.48M | 7.27M | 7.40M | 12.02M | 11.53M | 7.32M |
NeuroOne Medical Technologies Technical Analysis
Negative
0.62
Price Trends
0.69
Negative
0.88
Negative
0.86
Negative
Market Momentum
-0.01
Negative
45.17
Neutral
20.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NMTC, the sentiment is Negative. The current price of 0.62 is below the 20-day moving average (MA) of 0.63, below the 50-day MA of 0.69, and below the 200-day MA of 0.86, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 45.17 is Neutral, neither overbought nor oversold. The STOCH value of 20.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NMTC.
NeuroOne Medical Technologies Risk Analysis
NeuroOne Medical Technologies disclosed 51 risk factors in its most recent earnings report. NeuroOne Medical Technologies reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
NeuroOne Medical Technologies Peers Comparison
Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $5.14B | 3.23 | -45.01% | 2.85% | 17.55% | -0.69% | |
46 Neutral | $31.03M | ― | -265.18% | ― | 135.03% | 60.67% | |
43 Neutral | $11.19M | 0.91 | -499.57% | ― | -33.92% | ― | |
39 Underperform | $39.63M | ― | -104.36% | ― | ― | -1455.58% | |
38 Underperform | $34.76M | ― | 1697.39% | ― | -9.40% | -153.52% | |
35 Underperform | $12.17M | ― | -196.69% | ― | ― | ― | |
| $21.13M | ― | -367.74% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
NMTC
NeuroOne Medical Technologies
0.62
-0.36
-36.73%
PAVM
PAVmed
0.65
-0.92
-58.60%
RBOT
Vicarious Surgical
6.68
-3.25
-32.73%
IINN
Inspira Technologies Oxy BHN
0.48
-1.52
-76.00%
COCH
Envoy Medical
1.63
-0.99
-37.79%
NXL
Nexalin Technology, Inc.
1.23
0.31
33.70%
NeuroOne Medical Technologies Earnings Call Summary
Earnings Call Date:May 13, 2025
(Q2-2025)
| % Change Since: 0.00%|
Next Earnings Date:Aug 08, 2025
Earnings Call Sentiment Positive
The earnings call highlights a strong growth trajectory with significant increases in revenue and gross margins, successful capital raise, and positive clinical outcomes. However, there are challenges in maintaining revenue growth on a quarterly basis and the company continues to operate at a net loss, albeit improved. Overall, the company is well-positioned for future growth with new applications and strategic partnerships.Q2-2025 Updates
Positive Updates
Strong Revenue Growth
Product revenue increased 97% to $4.7 million in the first half of fiscal 2025 compared to the same period in fiscal 2024.
Significant Improvement in Gross Margins
Product gross margins increased to 57.9% in the first half of fiscal 2025, more than doubling from the first half of fiscal 2024.
Successful Capital Raise
The company raised $8.2 million in net proceeds from a successful capital raise, ensuring funding through at least fiscal 2026.
Positive Clinical Outcomes
Majority of patients treated with the OneRF ablation system are now seizure free, with one patient being seizure free for almost an entire year.
Expansion into New Applications
Filed a 510(k) submission with the FDA for the OneRF trigeminal nerve ablation system ahead of schedule, with potential revenue generation by late 2025.
Negative Updates
Flat Revenue in Q2
Product revenue was flat at $1.4 million in the second quarter of fiscal 2025 compared to $1.4 million in the same quarter of fiscal 2024.
Continued Net Loss
Net loss improved but remained at $2.3 million in the second quarter of fiscal 2025, compared to a net loss of $2.9 million in the same quarter of the previous year.
Company Guidance
In the second quarter of fiscal year 2025, NeuroOne Medical Technologies provided guidance indicating a significant increase in product revenue and gross margins. The company expects product revenue to range between $8 million and $10 million, representing an increase of 132% to 190% over fiscal 2024. Product gross margins are anticipated to be between 47% and 51%, up from 31% in the previous year. This guidance excludes the $3 million upfront license payment received from Zimmer Biomet. NeuroOne has also bolstered its financial position with a successful capital raise, adding $8.2 million in net proceeds, and the company believes it is fully funded through at least fiscal 2026. The company remains debt-free and is focused on ramping revenues through strategic partnerships and expanding its product offerings, particularly in international markets.NeuroOne Medical Technologies Corporate Events
Product-Related AnnouncementsPrivate Placements and FinancingBusiness Operations and Strategy
NeuroOne Advances with FDA Submission and Capital Raise
Positive
May 13, 2025
On May 13, 2025, NeuroOne Medical Technologies reported significant progress in its operations for the second quarter of fiscal year 2025. The company successfully filed an FDA submission for its OneRF® Trigeminal Nerve Ablation System ahead of schedule, potentially leading to revenue generation by late 2025. Additionally, NeuroOne completed an $8.2 million capital raise, ensuring funding through fiscal year 2026, and strengthened its management team. The company’s product revenue guidance for fiscal year 2025 is projected to increase significantly, with potential strategic partnerships in development for further applications of its technology.
The most recent analyst rating on (NMTC) stock is a Buy with a $1.45 price target. To see the full list of analyst forecasts on NeuroOne Medical Technologies stock, see the NMTC Stock Forecast page.
Delistings and Listing ChangesRegulatory Filings and Compliance
NeuroOne Faces Nasdaq Non-Compliance Notice
Negative
May 9, 2025
On May 6, 2025, NeuroOne Medical Technologies received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement, as its stock price was below $1.00 for 30 consecutive business days. The company has until November 3, 2025, to regain compliance or risk delisting, and is actively monitoring its stock price while considering options to address the issue.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.